Tapinarof 1% cream,
does it really help with Achievement of clear or almost-clear lesions in adult plaque psoriasis?
research showsThe grade is C. In 510 PSOARING 1 participants, week-12 PGA response was 35.4% versus 6.0%, a +29.4-point difference; in 515 PSOARING 2 participants it was 40.2% versus 6.3%, a +33.9-point difference. Lesion improvement was large, but both trials came from one Dermavant Sciences development program without independent replication, giving C with 54 points.
ads claimMarketing can expand a nonsteroidal topical option into long-term remission or cure of every form of psoriasis. The verified comparative evidence concerns once-daily treatment for 12 weeks in adults with plaque psoriasis, not permanent cure or efficacy in other inflammatory skin diseases.
Useful facts when choosing a product
- There is no separate physical or chemical claim; whether actual plaque psoriasis lesions become clear or almost clear is the graded claim.
- PSOARING 1 randomized and analyzed 510 participants, and PSOARING 2 randomized and analyzed 515; the week-12 PGA primary endpoint succeeded in both.
- Folliculitis and contact dermatitis were among local adverse events reported with tapinarof, so prescribing instructions and product labeling should be followed.
Chamgap Semantic Classification Code
Candidate index · review held
M.tapinarof-1-percent-cream.topical-skin.achievement-of-clear-or-almost-clear-lesions-plaque-psoriasis.assess.UNKMedicinal interventions > Tapinarof 1% cream > Topical skin > Achievement of clear or almost-clear lesions plaque psoriasis > Association or change assessment > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
PSOARING 1 randomized 510 participants, 340 to tapinarof and 170 to vehicle, and found PGA response of 35.4% versus 6.0%, difference +29.4 points. PSOARING 2 randomized 515, 343 and 172, and found 40.2% versus 6.3%, difference +33.9 points. Both 12-week trials were funded by Dermavant Sciences. Folliculitis was 80/340 (23.5%) versus 2/170 (1.2%) and 61/343 (17.8%) versus 1/172 (0.6%); contact dermatitis was 17/340 (5.0%) versus 1/170 (0.6%) and 20/343 (5.8%) versus 0/172 (0%).
Why this is classified as C (54)
A large direct lesion effect appeared in two replicate phase 3 trials, but decisive evidence is confined to one manufacturer program, giving C with 54 points. Local adverse events affect safety reporting, not the efficacy grade.
Counterpoint. C reflects limited independence rather than absence of efficacy. A long-term confirmatory trial independent of manufacturers could support upgrading.
Rejudgment record. Cross-check applied — The direct lesion endpoint succeeded by large margins in two 12-week trials, but decisive evidence is confined to the Dermavant program without external independent replication
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Achievement of week-12 PGA response | C | Rates were 35.4% to 40.2% versus 6.0% to 6.3% with vehicle in two replicate trials. |
| Achievement of PASI 75 at week 12 | C | The secondary lesion endpoint also favored tapinarof in both trials. |
| Improvement of itch during treatment | C | Patient-reported improvement was observed but came from secondary outcomes in the same manufacturer program. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Lebwohl MG et al. 2021 PSOARING 1 and 2 | Multicenter double-blind randomized vehicle-controlled replicate phase 3 trials | PSOARING 1 randomized and analyzed 510; PSOARING 2 randomized and analyzed 515 | Manufacturer funding from Dermavant Sciences | Week-12 PGA response: clear or almost clear with at least a two-grade improvement from baseline | PSOARING 1 found 35.4% versus 6.0%, difference +29.4 points; PSOARING 2 found 40.2% versus 6.3%, difference +33.9 points. Both lasted 12 weeks. | Pivotal manufacturer-funded replicate phase 3 evidence |
| Stein Gold L et al. 2021 phase 2b trial | Double-blind randomized dose-ranging vehicle-controlled phase 2b trial | 227 adults with plaque psoriasis randomized | Supported by Dermavant Sciences with manufacturer employees as coauthors | Week-12 lesion assessments and patient-reported symptoms | Supported lesion and symptom improvement with the 1% formulation but did not provide independent replication. | Supportive evidence from the same manufacturer program |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Tapinarof 1% cream x improvement of plaque psoriasis lesions — Evidence Grade C·54. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/tapinarof-plaque-psoriasis-skin-clearance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.